BRISTOL MYERS SQUIBB
BMS-986446
This clinical trial’s goal is to determine the impact BMS-986446 on cognitive and functional decline in participants with early Alzheimer’s disease. BMS-986446 is an anti-MTBR Tau Monoclonal antibody.
Eligibility: Individuals who have mild cognitive impairment (MCI) or early Alzheimer’s disease.
Status: RECRUITING